12:00 AM
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pixantrone regulatory update

Cell Therapeutics completed submission of a rolling NDA to FDA for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma. The company requested Priority Review for...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >